Nektar Therapeutics (NKTR) Gross Profit (2010 - 2026)

Nektar Therapeutics' Gross Profit history runs 17 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Gross Profit rose 146.46% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $85.8 million (up 81.77% YoY), while the FY2025 annual figure was $55.2 million, down 2.04% from the prior year.
• Gross Profit was $3.2 million for Q1 2026 at Nektar Therapeutics, down from $59.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $59.7 million in Q4 2025 to a low of -$6.8 million in Q1 2025.
• Historically, Gross Profit has averaged $15.9 million across 5 years, with a median of $14.5 million in 2023.
• Biggest YoY gain for Gross Profit was 190.17% in 2025; the steepest drop was 165.17% in 2025.
• A 5-year view of Gross Profit shows it stood at $15.8 million in 2022, then gained by 5.14% to $16.6 million in 2023, then climbed by 23.9% to $20.6 million in 2024, then surged by 190.17% to $59.7 million in 2025, then slumped by 94.71% to $3.2 million in 2026.
• The last three Gross Profit figures came in at $3.2 million (Q1 2026), $59.7 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.